Literature DB >> 9892010

Somatostatin activation of mitogen-activated protein kinase via somatostatin receptor 1 (SSTR1).

T Florio1, H Yao, K D Carey, T J Dillon, P J Stork.   

Abstract

Hormones and growth factors regulate cell growth via the mitogen-activated protein (MAP) kinase cascade. Here we examine the actions of the hormone somatostatin on the MAP kinase cascade through one of its two major receptor subtypes, the somatostatin receptor 1 (SSTR1) stably expressed in CHO-K1 cells. Somatostatin antagonizes the proliferative effects of fibroblast growth factor in CHO-SSTR1 cells via the SSTR1 receptor. However, in these cells, somatostatin robustly activates MAP kinase (also called extracellular signal regulated kinase; ERK) and augments fibroblast growth factor-stimulated ERK activity. We show that the activation of ERK via SSTR1 is pertussis toxin sensitive and requires the small G protein Ras, phosphatidylinositol 3-kinase, the serine/threonine kinase Raf-1, and the protein tyrosine phosphatase SHP-2. The activation of ERK by SSTR1 increased the expression of the cyclin-dependent protein kinase inhibitor p21(cip1/WAF1). Previous studies have suggested that somatostatin-stimulated protein tyrosine phosphatase activity mediates the growth effects of somatostatin. Our data suggest that SHP-2 stimulation by SSTR1 may mediate some of these effects through the activation of the MAP kinase cascade and the expression of p21(cip1/WAF1).

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9892010     DOI: 10.1210/mend.13.1.0224

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  22 in total

1.  Critical role of Src and SHP-2 in sst2 somatostatin receptor-mediated activation of SHP-1 and inhibition of cell proliferation.

Authors:  Geraldine Ferjoux; Frederic Lopez; Jean-Pierre Esteve; Audrey Ferrand; Eric Vivier; Frederic Vely; Nathalie Saint-Laurent; Lucien Pradayrol; Louis Buscail; Christiane Susini
Journal:  Mol Biol Cell       Date:  2003-07-11       Impact factor: 4.138

Review 2.  International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.

Authors:  Thomas Günther; Giovanni Tulipano; Pascal Dournaud; Corinne Bousquet; Zsolt Csaba; Hans-Jürgen Kreienkamp; Amelie Lupp; Márta Korbonits; Justo P Castaño; Hans-Jürgen Wester; Michael Culler; Shlomo Melmed; Stefan Schulz
Journal:  Pharmacol Rev       Date:  2018-10       Impact factor: 25.468

3.  Somatostatin activates Ras and ERK1/2 via a G protein βγ-subunit-initiated pathway in thyroid cells.

Authors:  Francisco J Rodríguez-Álvarez; Eva Jiménez-Mora; María Caballero; Beatriz Gallego; Antonio Chiloeches; Ma José Toro
Journal:  Mol Cell Biochem       Date:  2015-10-16       Impact factor: 3.396

4.  Protein-tyrosine-phosphatase-mediated epidermal growth factor (EGF) receptor transinactivation and EGF receptor-independent stimulation of mitogen-activated protein kinase by bradykinin in A431 cells.

Authors:  A Graness; S Hanke; F D Boehmer; P Presek; C Liebmann
Journal:  Biochem J       Date:  2000-04-15       Impact factor: 3.857

5.  Somatostatin receptor (SSTR) expression and function in normal and leukaemic T-cells. Evidence for selective effects on adhesion to extracellular matrix components via SSTR2 and/or 3.

Authors:  T Talme; J Ivanoff; M Hägglund; R J Van Neerven; A Ivanoff; K G Sundqvist
Journal:  Clin Exp Immunol       Date:  2001-07       Impact factor: 4.330

6.  Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors.

Authors:  Jonathan Strosberg; Larry Kvols
Journal:  World J Gastroenterol       Date:  2010-06-28       Impact factor: 5.742

7.  Somatostatin receptor-1 induces cell cycle arrest and inhibits tumor growth in pancreatic cancer.

Authors:  Min Li; Xiaochi Wang; Wei Li; Fei Li; Hui Yang; Hao Wang; F Charles Brunicardi; Changyi Chen; Qizhi Yao; William E Fisher
Journal:  Cancer Sci       Date:  2008-09-22       Impact factor: 6.716

8.  Subtype selective interactions of somatostatin and somatostatin analogs with sst1, sst2, and sst5 in BON-1 cells.

Authors:  Eva Ludvigsen; Mats Stridsberg; John E Taylor; Michael D Culler; Kjell Oberg; Eva T Janson
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

9.  Tyr-c[D-Orn-Tyr(Bzl)-Pro-Gly]: a novel antiproliferative acting somatostatin receptor agonist with mu-opioid receptor-sensitizing properties.

Authors:  Jörg Stirnweiss; Bianka Hartrodt; Gisela Greksch; Uta Stürzebecher; Frank-D Böhmer; Klaus Neubert; Claus Liebmann
Journal:  Br J Pharmacol       Date:  2003-08-04       Impact factor: 8.739

Review 10.  Evolving treatment strategies for management of carcinoid tumors.

Authors:  Jonathan Strosberg
Journal:  Curr Treat Options Oncol       Date:  2013-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.